Amanote Research
Register
Sign In
Antibody–Drug Conjugate Hits Elusive HER2 + Breast Tumors
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2013-051
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
April 6, 2013
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Molecular Cancer Therapeutics
Cancer Research
Oncology
Anti-Cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study
Pharmaceutical Research
Organic Chemistry
Biotechnology
Molecular Medicine
Pharmacology
Pharmaceutical Science
Preclinical Evaluation of a GFRA1 Targeted Antibody-Drug Conjugate in Breast Cancer
Oncotarget
Oncology
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
Cancer Cell
Cancer Research
Oncology
Cell Biology
Studies on Antibody-Anticancer Drug Conjugate
Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
Cancer Cell
Cancer Research
Oncology
Cell Biology
T-Dm1, a Novel Antibody-Drug Conjugate, Is Highly Effective Against Uterine and Ovarian Carcinosarcomas Overexpressing HER2
Clinical and Experimental Metastasis
Medicine
Cancer Research
Oncology
The Latest Research and Development Into the Antibody–Drug Conjugate, [Fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Chemical and Pharmaceutical Bulletin
Medicine
Drug Discovery
Chemistry
Tumor Stroma–targeted Antibody-Drug Conjugate Triggers Localized Anticancer Drug Release
Journal of Clinical Investigation
Medicine
